Transurethral holmium laser enucleation of prostate shows remarkable efficacy in treating benign prostatic hyperplasia
Abstract
OBJECTIVE
To evaluate the effects of transurethral holmium laser enucleation of the prostate (HoLEP) in treating benign prostatic hyperplasia (BPH).
METHODS
This retrospective study included 100 BPH patients who visited Foshan Fosun Chancheng Hospital from January 2022 to June 2023. Patients were divided into two groups: 50 treated with transurethral resection of the prostate (control group) and 50 with transurethral HoLEP (observation group). We compared clinical efficacy, surgical parameters, maximum urinary flow rate (Qmax), post-void residual volume (PRV), prostate-specific antigen (PSA), hemoglobin (Hb), interleukin-6 (IL-6), C-reactive protein (CRP), International Prostate Symptom Score (IPSS), quality of life (QOL), and complication rates.
RESULTS
The observation group showed significantly reduced operative time, blood loss, catheterization duration, and hospitalization compared to the control group (all P<0.05). Postoperatively, Qmax was higher and PRV lower in the observation group (both P<0.05). PSA was lower, and Hb was higher in the observation group than those in the control group (both P<0.05). Both IL-6 and CRP levels increased post-surgery, but were significantly lower in the observation group (both P<0.05). The observation group also had better IPSS and QOL scores and a lower complication rate (16% vs. 56%, all P<0.05).
CONCLUSION
HoLEP is an effective treatment for BPH, offering advantages such as reduced surgical time, lower complication rates, improved…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.